• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

SynAct Pharma

14.50 SEK

-0.28 %

Less than 1K followers

SYNACT

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-0.28 %
-2.42 %
-20.07 %
-35.84 %
-31.92 %
-14.71 %
-79.82 %
-84.69 %
+214.56 %

SynAct Pharma operates in the pharmaceutical industry and focuses on the development of innovative treatments for inflammatory diseases. The company researches new therapies that can reduce inflammation and improve patient outcomes. The business is global with a primary presence in Europe and North America. SynAct Pharma was founded in 2012 and is headquartered in Lund, Sweden.

Read more
Market cap
815.1M SEK
Turnover
4.53M SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
3rd party
ShowingAll content types

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
20/8
2026

Interim report Q2'26

3/11
2026

Interim report Q3'26

18/2
2027

Annual report '26

Press release15 hours ago

SynAct erhåller viktigt patent i USA för resomelagon och säkrar exklusivitet till 2044

SynAct Pharma
Press release15 hours ago

SynAct obtains key US patent for resomelagon securing exclusivity until 2044

SynAct Pharma
Regulatory press releaseyesterday

Kommuniké från årsstämma 2026 i SynAct Pharma AB

SynAct Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press releaseyesterday

Report from the 2026 Annual General Meeting of SynAct Pharma AB (publ)

SynAct Pharma
Press release5/28/2026, 4:34 PM

Redeye: SynAct (Q1 Update): ADVANCE Topline in June

SynAct Pharma
Regulatory press release5/27/2026, 5:30 AM

SynAct Pharma publicerar delårsrapport Q1 2026

SynAct Pharma
Regulatory press release5/27/2026, 5:30 AM

SynAct Pharma publishes Q1 2026 interim results

SynAct Pharma
Press release5/26/2026, 8:20 AM

SynAct Pharma informerar om större aktieägares handel i bolagets aktie

SynAct Pharma
Press release5/26/2026, 6:58 AM

Synact Pharma large shareholder trading update

SynAct Pharma
Press release5/19/2026, 12:00 PM

SynAct Pharma presenterar på BioStock Global Forum 2026 den 21 maj

SynAct Pharma
Press release5/19/2026, 12:00 PM

SynAct Pharma to present at the BioStock Global Forum 2026 on May 21

SynAct Pharma
Regulatory press release5/8/2026, 4:55 PM

Kallelse till årsstämma i SynAct Pharma AB

SynAct Pharma
Regulatory press release5/7/2026, 8:00 AM

Notice of annual general meeting in SynAct Pharma AB

SynAct Pharma
Press release5/6/2026, 9:29 AM

BioStock: SynAct Pharma completes dosing in phase IIb ADVANCE study ahead of June readout

SynAct Pharma
Press release5/6/2026, 5:00 AM

SynAct Pharma slutför dosering av sista patienten i fas 2b-studien ADVANCE

SynAct Pharma
Press release5/6/2026, 5:00 AM

SynAct Pharma completes dosing for last patient in Phase 2b ADVANCE study

SynAct Pharma
Press release5/5/2026, 9:30 AM

SynAct Pharma deltar vid LSX Nordic Congress den 19–20 maj 2026 i Köpenhamn

SynAct Pharma
Press release5/5/2026, 9:30 AM

SynAct Pharma to participate at the LSX Nordic Congress on May 19-20, 2026 in Copenhagen

SynAct Pharma
Press release4/27/2026, 7:07 AM

BioStock: What good data looks like: SynAct Pharma ahead of its ADVANCE readout

SynAct Pharma
Regulatory press release4/23/2026, 5:00 PM

SynAct Pharmas valberedning inför årsstämman 2026

SynAct Pharma